Class of Stock [Axis]
Common Stock, par value $0.0001 per share
Redeemable Warrants, each whole warrant exercisable for one share of Common Stock
Related and Nonrelated Parties [Axis]
Nonrelated Party [Member]
Related Party [Member]
Equity Components [Axis]
Common Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
AOCI Attributable to Parent [Member]
Investment, Name [Axis]
Sarborg Limited [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Axis]
Equity Purchase Agreement [Member]
Business Combination [Axis]
Pre-funded Warrants [Member]
Debt Instrument [Axis]
AGP Convertible Note [Member]
Ascent Note [Member]
Fair Value Hierarchy and NAV [Axis]
Fair Value, Inputs, Level 1 [Member]
Measurement Frequency [Axis]
Fair Value, Recurring [Member]
Derivative Instrument [Axis]
Cash and Cash Equivalents [Member]
Fair Value, Inputs, Level 2 [Member]
Fair Value, Inputs, Level 3 [Member]
Convertible Notes Payable [Member]
Warrant [Member]
Measurement Input Type [Axis]
Measurement Input, Share Price [Member]
Measurement Input, Expected Term [Member]
Corporate Bond Yield Estimated Timing of Conversion [Member]
Measurement Input, Credit Spread [Member]
Measurement Input Probability of Default [Member]
Measurement Input Recovery Upon Default [Member]
Measurement Input, Price Volatility [Member]
Legal Entity [Axis]
Alliance Global Partners [Member]
Alliance Gobal Partners Convertible Note [Member]
Convertible Note Binomial Lattice Model [Member]
Subsequent Event Type [Axis]
Subsequent Event [Member]
Short-Term Debt, Type [Axis]
Convertible Promissory Note [Member]
SARBORG Service Agreement [Member]
Service Agreement [Member]
SARBORG Additional Agreement [Member]
Second Additional Agreement [Member]
Manoira Joint Development Agreement [Member]
Plan Name [Axis]
2023 Stock Incentive Plan [Member]
Title and Position [Axis]
Director [Member]
Award Type [Axis]
2023 Plan [Member]
Sales Agreement [Member]
Investment Objective [Axis]
Investor [Member]
Antidilutive Securities [Axis]
Public Warrants [Member]
A.G.P. Warrants [Member]
Convertible Promissory Notes Payable [Member]
Equity Option [Member]
March 2024 Warrants [Member]
April 2024 Warrants [Member]
AGP 2024 Warrants [Member]
Corvus Capital Limited [Member]
Board of Directors [Member]
SARBORG Ltd [Member]
SARBORG Services Agreement [Member]
Joint Development Agreement [Member]
Lease Agreement [Member]
Purchase Agreement Corvus [Member]
Segments [Axis]
Clinical Asset Development [Member]
Related Parties [Member]
Legal and Professional Fees [Member]
Accounting and Audit Fees [Member]
Salaries Payroll and Stock Based Compensation [Member]
Other [Member]
ELOC [Member]
ELOC Amendment No. 2 [Member]
Senior Secured Promissory Note with J.J. Astor and Co [Member]
Twenty Four Equal Weekly Installments [Member]
Statement [Table]
Statement [Line Items]
Document Type
Amendment Flag
Amendment Description
Document Registration Statement
Document Annual Report
Document Quarterly Report
Document Transition Report
Document Shell Company Report
Document Shell Company Event Date
Document Period Start Date
Document Period End Date
Document Fiscal Period Focus
Document Fiscal Year Focus
Current Fiscal Year End Date
Entity File Number
Entity Registrant Name
Entity Central Index Key
Entity Primary SIC Number
Entity Tax Identification Number
Entity Incorporation, State or Country Code
Entity Address, Address Line One
Entity Address, Address Line Two
Entity Address, Address Line Three
Entity Address, City or Town
Entity Address, State or Province
Entity Address, Country
Entity Address, Postal Zip Code
Country Region
City Area Code
Local Phone Number
Extension
Written Communications
Soliciting Material
Pre-commencement Tender Offer
Pre-commencement Issuer Tender Offer
Title of 12(b) Security
No Trading Symbol Flag
Trading Symbol
Security Exchange Name
Title of 12(g) Security
Security Reporting Obligation
Annual Information Form
Audited Annual Financial Statements
Entity Well-known Seasoned Issuer
Entity Voluntary Filers
Entity Current Reporting Status
Entity Interactive Data Current
Entity Filer Category
Entity Small Business
Entity Emerging Growth Company
Elected Not To Use the Extended Transition Period
Document Accounting Standard
Other Reporting Standard Item Number
Entity Shell Company
Entity Public Float
Entity Bankruptcy Proceedings, Reporting Current
Entity Common Stock, Shares Outstanding
Documents Incorporated by Reference [Text Block]
Entity Listing, Par Value Per Share
Defined Benefit Plan [Table]
Defined Benefit Plan Disclosure [Line Items]
ASSETS
Current assets
Cash and cash equivalents
Prepaid R&D services- related party (see Note 8 and Note 13)
Prepaid R&D services
Prepaid expenses and other current assets
Total current assets
Equity method investments
Operating lease right-of-use assets, net
Equipment and clinical assets, net
Prepaid expenses and other long-term assets
Total assets
LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)
Current liabilities
Accounts payable
Investment payable
Accrued expenses and other current liabilities
Accrued litigation liability
Operating lease liability, current portion
Convertible promissory notes payable at fair value
Notes payable
Total current liabilities
Total liabilities
Commitments and contingencies (see Note 15)
Stockholders’ equity (deficit)
Common stock, par value $0.0001; 250,000,000 shares authorized at March 31, 2026 and December 31, 2025, respectively, 4,722,457 shares and 92,140 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively
Preferred stock, par value $0.0001; 1,000,000 shares authorized at March 31, 2026 and December 31, 2025, respectively; nil shares issued and outstanding at March 31, 2026 and December 31, 2025
Additional paid-in capital
Accumulated deficit
Accumulated other comprehensive income (loss)
Total stockholders’ equity (deficit)
Total liabilities and stockholders’ equity (deficit)
Statement of Financial Position [Abstract]
Common stock, par value
Common stock, shares authorized
Common stock, shares issued
Common stock, shares outstanding
Preferred stock, par value
Preferred stock, shares authorized
Preferred stock, shares issued
Preferred stock, shares outstanding
Income Statement [Abstract]
Operating expenses:
Research and development expenses
General and administrative expenses
Total operating expenses
Operating loss
Other income (expense):
Other expense, net
Loss on equity method investment
Interest income
Interest expense
Total other expense, net
Net loss
Basic net loss per share
Diluted net loss per share
Basic weighted-average common shares outstanding
Diluted weighted-average common shares outstanding
Comprehensive loss:
Foreign currency translation adjustment
Total comprehensive loss
Balance, value
Balance, shares
Issuance of Common Stock for services
Issuance of Common Stock for services, shares
Issuance of Common Stock upon exercise of conversion option
Issuance of Common Stock upon Exercise of Conversion Option, shares
Stock-based compensation
Stock-based compensation, shares
Shares issued for equity line of credit
Shares issued for equity line of credit, shares
Issuance of common stock upon investment
Issuance of common stock upon investment, shares
Issuance of warrants upon investment
Exercise of warrants attributable to investment
Exercise of warrants attributable to investment, shares
Exercise of warrants attributable to the sale of previously controlled subsidiary
Exercise of warrants attributable to the sale of preciously controlled subsidiary, shares
Foreign currency translation adjustment
Net loss
Issuance of Common Stock under the ATM Program
Issuance of Common Stock under the ATM Program, shares
Stock-based compensation
Stock-based compensation, shares
Balance, value
Balance, shares
Statement of Cash Flows [Abstract]
Cash flows from operating activities:
Adjustments to reconcile net loss to net cash used in operating activities:
Loss on debt extinguishment, net
Unrealized foreign exchange gain
Change in fair value of convertible notes payable
Gain on change in fair value of derivative warrant liability
Loss on equity method investment
Gain on waiver of accrued interest
Stock-based compensation expense
Non-cash interest expense
Operating lease obligations
Depreciation expense
Amortization of financed directors and officers insurance
Issuance of common stock for services
Amortization expense
Changes in operating assets and liabilities:
Prepaid expenses and other current assets
Accounts payable
Accrued expenses and other liabilities
Lease liability
Net cash flows used in operating activities
Cash flows from investing activities:
Purchases of equipment and clinical assets
Net cash flows used in investing activities
Cash flows from financing activities:
Net proceeds from the issuance of notes payable
Proceeds from issuance of common shares related to the ATM program
Repayment of notes payable – related parties
Repayment of notes payable
Repayment of convertible notes payable – related parties
Repayment of convertible notes payable
Net cash flows provided by financing activities
Net change in cash and cash equivalents before effect of exchange rate changes
Effect of exchange rate changes on cash and cash equivalents
Net change in cash
Cash and cash equivalents at beginning of period
Cash and cash equivalents at end of period
Supplemental cash flow information:
Cash paid for interest
Cash paid for taxes
Non-cash investing and financing activities
Issuance of common stock upon exercise of conversion option
Issuance of common stock for investment in related party
Deferred cash payable for investment in related party
Issuance of pre-funded warrants for investment in related party
Pay vs Performance Disclosure [Table]
Executive Category [Axis]
Individual [Axis]
Adjustment to Compensation [Axis]
Measure [Axis]
Pay vs Performance Disclosure, Table
Company Selected Measure Name
Named Executive Officers, Footnote
Peer Group Issuers, Footnote
Changed Peer Group, Footnote
PEO Total Compensation Amount
PEO Actually Paid Compensation Amount
Adjustment To PEO Compensation, Footnote
Non-PEO NEO Average Total Compensation Amount
Non-PEO NEO Average Compensation Actually Paid Amount
Adjustment to Non-PEO NEO Compensation Footnote
Equity Valuation Assumption Difference, Footnote
Compensation Actually Paid vs. Total Shareholder Return
Compensation Actually Paid vs. Net Income
Compensation Actually Paid vs. Company Selected Measure
Total Shareholder Return Vs Peer Group
Compensation Actually Paid vs. Other Measure
Tabular List, Table
Total Shareholder Return Amount
Peer Group Total Shareholder Return Amount
Net Income (Loss)
Company Selected Measure Amount
Other Performance Measure, Amount
Adjustment to Compensation, Amount
PEO Name
Name
Non-GAAP Measure Description
Additional 402(v) Disclosure
Pension Benefits Adjustments, Footnote
Equity Awards Adjustments, Footnote
Erroneously Awarded Compensation Recovery [Table]
Restatement Determination Date [Axis]
Restatement Determination Date
Aggregate Erroneous Compensation Amount
Erroneous Compensation Analysis
Stock Price or TSR Estimation Method
Outstanding Aggregate Erroneous Compensation Amount
Aggregate Erroneous Compensation Not Yet Determined
Name
Forgone Recovery due to Expense of Enforcement, Amount
Forgone Recovery due to Violation of Home Country Law, Amount
Forgone Recovery due to Disqualification of Tax Benefits, Amount
Forgone Recovery, Explanation of Impracticability
Name
Compensation Amount
Restatement does not require Recovery
Awards Close in Time to MNPI Disclosures [Table]
Award Timing MNPI Disclosure
Award Timing Method
Award Timing Predetermined
Award Timing MNPI Considered
Award Timing, How MNPI Considered
MNPI Disclosure Timed for Compensation Value
Awards Close in Time to MNPI Disclosures, Table
Name
Underlying Securities
Exercise Price
Fair Value as of Grant Date
Underlying Security Market Price Change
Insider Trading Arrangements [Line Items]
Material Terms of Trading Arrangement
Name
Title
Rule 10b5-1 Arrangement Adopted
Non-Rule 10b5-1 Arrangement Adopted
Adoption Date
Rule 10b5-1 Arrangement Terminated
Non-Rule 10b5-1 Arrangement Terminated
Termination Date
Expiration Date
Arrangement Duration
Aggregate Available
Non-Rule 10b5-1 Arrangement Modified
Non-Rule 10b5-1 Arrangement Modified
Insider Trading Policies and Procedures [Line Items]
Insider Trading Policies and Procedures Adopted
Insider Trading Policies and Procedures Not Adopted
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of the Business
Liquidity And Going Concern
Liquidity and Going Concern
Accounting Policies [Abstract]
Basis of Presentation and Summary of Significant Accounting Policies
Equity Method Investments and Joint Ventures [Abstract]
Investments
Fair Value Disclosures [Abstract]
Fair Value
Balance Sheet Details
Convertible Notes Payable
Convertible Notes Payable
Research And Development Expense
Research and Development Expense
Share-Based Payment Arrangement [Abstract]
Share Based Compensation
Income Tax Disclosure [Abstract]
Income Taxes
Equity [Abstract]
Common Stock and Preferred Stock
Earnings Per Share [Abstract]
Net Loss Per Share Attributable to Common Stockholders
Related Party Transactions [Abstract]
Related Party Transactions
Other Income and Expenses [Abstract]
Other Expense, net
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies
Warrants
Warrants
Segment Reporting [Abstract]
Segments
Subsequent Events [Abstract]
Subsequent Events
Basis of Presentation
Principles of Consolidation
Other Risks and Uncertainties
Use of Estimates
Fair Value Measurements
Fair Value Option
Investments
ELOC
Foreign Currency Translation
Recently Issued Accounting Standards Adopted
Recently Issued Accounting Standards Not Yet Adopted
Schedule of Investment in Sarborg Using Cost Method
Summary of Financial Information for Sarborg
Short-Term Debt [Table]
Short-Term Debt [Line Items]
Schedule of Assets Subject to Measurement at Fair Value on Recurring Basis
Schedule of Additional Information About the Financial Liabilities Subject To Measurement at Fair Value
Schedule of Fair Value of Assumptions
Schedule of Balance Sheet Details
Schedule of Accrued Expenses and Other Current Liabilities
Schedule of Stock Option Activity
Schedule of Potentially Dilutive Securities
Schedule of Other Expense, Net
Schedule of Financial Data for the Company’s Reportable Segment
Reverse stock splits
Retained Earnings (Accumulated Deficit)
Cash, Cash Equivalents, and Short-Term Investments
Operating Income (Loss)
Cash provided by operating activities
Proceeds from market offering program
AccountingPoliciesTable [Table]
Equity Method Investment, Description of Principal Activities
Issuance common stock
Common Stock, par value
Common stock, voting rights
Share price
Minimum price per share
Balance as of December 31, 2025
Investment in Sarborg
Loss on equity investment in Sarborg
Impairment on equity investment in Sarborg
Balance as of March 31, 2026
Current assets
Non-current assets
Current liabilities
Net liabilities
Company share of net liabilities
Revenue
Company share of net loss
Equity Method Investment [Table]
Schedule of Equity Method Investments [Line Items]
Equity interest percent
Business Combination, Consideration Transferred, Equity Interest, Share Issued, Value
Business Combination, Consideration Transferred, Equity Interest, Share Issued, Number of Shares
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right
Cash payable
Facility Costs
Increase (Decrease) in Partners' Capital
Cash
Exercise price
Warrants issued, shares
Cashless exercise, shares
Loss on investments
Equity method investments, carrying value
Fair Value, off-Balance-Sheet Risk [Table]
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Total Assets
Total Liabilities
Balance as of December 31, 2025
Fair value at issuance
Conversion of convertible notes
Interest expense
Change in fair value
Balance as of March 31, 2026
Fair Value Measurement Inputs and Valuation Techniques [Table]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Measurement input
Measurement input term
Prepaid expenses
Tax receivable
Prepaid directors’ and officers’ insurance
Total prepaid expenses and other current assets
Accrued professional fees
Accrued legal contingency
HMRC payable
Accrued other
Total accrued expenses and other current liabilities
DisclosureConvertibleNotesPayableTable [Table]
Proceeds from Fees Received
Stock Issued During Period, Shares, New Issues
Class of Warrant or Right, Number of Securities Called by Warrants or Rights
Class of Warrant or Right, Exercise Price of Warrants or Rights
Payments for Other Fees
Deferred commission payable annual interest rate
Debt Instrument, Increase, Accrued Interest
Other Income
Principal amount
Conversion percentage
Convertible note
Notes Payable, Fair Value Disclosure
Common stock
Loss on conversion amount
Interest rate
Debt valuation amount
Gain loss on change in fair value
Contractual interest expense
Converted remaining principal and interest shares
Maturity date
Proceeds from Convertible Debt
Fair value of Ascent note
ResearchAndDevelopmentExpenseTable [Table]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Cash payment
Shares, value
Shares issued
Payable in cash
Amortization expense
Intangible Assets, Current
Agreement related expense
Prepaid Expense
Shares Issued, Price Per Share
Fair value of asset acquired
Consideration payable
Research and development expense
Share Price
Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Options, Outstanding
Weighted Average Exercise Price, Outstanding
Weighted Average Remaining Contractual Term Years
Aggregate Intrinsic Value
Number of Options, Granted
Weighted Average Exercise Price, Granted
Number of Options, Cancelled/forfeited
Weighted Average Exercise Price, Cancelled/Forfeited
Number of Options, Exercised
Weighted Average Exercise Price, Exercised
Number of Options, Outstanding
Weighted Average Exercise Price, Outstanding
Aggregate Intrinsic Value
Number of Options, Exercisable
Weighted Average Exercise Price, Exercisable
Weighted Average Remaining Contractual Term Years
Aggregate Intrinsic Value
Number of Options, Unvested
Weighted Average Exercise Price, Unvested
Weighted Average Remaining Contractual Term Years
Aggregate Intrinsic Value
Issuance of common stock
Shares issued percentage
Issuance unregistered shares of Common Stock
Number of authorized shares
Stock Issued During Period, Value, New Issues
Other Expenses
Shares granted
Cost related to non-vested option
Weighted average remaining vesting
Stock-based compensation expense recognized
Income tax, description
Effective tax rate
Accumulated Other Comprehensive Income (Loss) [Table]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Net proceeds
Sale of stock, percentage
Sale of stock
Issuance costs
Equity method investment ownership percentage
Issuance of common stock upon investment
Issuance of common stock upon investment, price per share
Issuance of common stock upon investment, value
Antidilutive Security, Excluded EPS Calculation [Table]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities
Related Party Transaction [Table]
Related Party Transaction [Line Items]
Common Stock, Shares Subscribed but Unissued
Travel expenses payable
Purchase of asset
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number
Fair Value of Assets Acquired
Prepaid expense
Proceeds from Issuance of Common Stock
Unrealized foreign currency transaction gain
Gain on change in fair value of derivative warrant liability
Gain on change in fair value of convertible notes payable
Interest income
Gain on debt extinguishment
Gain on waiver of accrued interest
Gain on the issuance of shares for services
Total other income:
Loss on the change in fair value of convertible notes payable
Interest expense
Loss on equity method investment
Other
Total other expense
Loss Contingencies [Table]
Litigation Settlement, Fee Expense
Business Combination common stock on market value, stand
Interest and repayment on strand's costs
Strands costs
Accrued Liabilities, Current
Area of land
Operating lease right of use asset
Operating lease liability
Short-term lease liability
Future minimum lease payments remaining
DisclosureWarrantsTable [Table]
Class of Warrant or Right, Outstanding
Segment Reporting [Table]
Segment Reporting [Line Items]
Research & development expense
General and administrative expenses
Total operating costs and expenses
Other Expenses:
Other expense
Loss on investment
Interest Income
Interest expense, net
Operating segment
Subsequent Event [Table]
Subsequent Event [Line Items]
Convertible note converted of principal
Convertible note converted of interest into shares
Sale of new shares
Gross purchase price to be paid
Proceeds from convertible note
Note payable to periodic payment
Common stock purchase warrants
Common Stock an exercise price
Repayments of debt
Redeemable Warrants, each whole warrant exercisable for one share of Common Stock
Common Stock, par value $0.0001 per share
Rule 10b5-1 Arrangement Modified.
Non-Rule 10b5-1 Arrangement Modified.
Prepaid rd services related party
Prepaid rd services.
Prepaid expense and other long term assets noncurrent.
Accrued litigation liability
Stocki ssued during period value issuance of common stock upon exercise of conversion option
Stock issued during period shares issuance of common stock upon exercise of conversion option.
Stock issued during period value for equity line of credit.
Stock issued during period shares for equity line of credit.
Stock issued during period value issuance of common stock upon investment.
Stock issued during period shares issuance of common stock upon investment shares.
Stock issued during period value exercise of warrants attributable to investment.
Stock issued during period shares exercise of warrants attributable to investment shares.
Stock issued during period value exercise of warrants attributable to sale of preciously controlled subsidiary.
Stock issued during period shares exercise of warrants attributable to sale of preciously controlled subsidiary shares.
Stock issued during period value issuance of common stock.
StockIssuedDuringPeriodSharesIssuanceOfCommonStock
Loss on debt extinguishment net.
Loss on change in fair value of convertible notes payable.
Gains on waiver of accrued interest.
Loss on disposal of crypto holdings
Noncash lease expense.
Non-cash interest expense.
Operating lease obligations.
Depreciation expense.
Amortization of debt discount.
Increase decrease in accrued expenses and other current liabilities.
Gain on change in fair value of convertible notes payable.
Purchase of equipment and clinical assets.
Repayment of notes payable related parties.
Repayment of convertible notes payable - related parties.
Issuance of common stock for investment in related party.
Issuance of pre-funded warrants for investment in related party.
Issuance of common stock upon exercise of conversion option.
Liquidity And Going Concern [Text Block]
Other Risks And Uncertainties [Policy Text Block]
Deposit insurance limit.
Cash and cash equivalents net bank overdrafts.
Equity Line of Credit Facility [Policy Text Block]
Equity Purchase Agreement [Member]
Minimum price per share.
Equipment and Clinical Assets [Policy Text Block]
Warrant Instruments [Policy Text Block]
Stock Options [Policy Text Block]
New Accounting Pronouncements Not Yet Adopted [Policy Policy Text Block]
Sales Of Wholly Owned Subsidiary Disclosure [Text Block]
Sale and Purchase Agreement [Member]
Pre-funded Warrants [Member]
Plaintiff for cash advisory fees
Legal cost reimbursement
Legal cost reimbursement total
Loss on deconsolidation of previously controlled subsidiary.
Sarborg Limited [Member]
Net liabilities.
Company share of net liabilities.
Company share of net loss.
Change in fair value of convertible notes payable.
AGP Convertible Note [Member]
Corporate Bond Yield Estimated Timing of Conversion [Member]
Measurement Input Probability of Default [Member]
Measurement Input Recovery Upon Default [Member]
Ascent Note [Member]
Accrued contingency
Equity method investment payable - related party.
Convertible Notes Payable [Text Block]
Convertible Promissory Notes Payable [Member]
2023 Convertible Note [Member]
Convertible Promissory Note Payable [Member]
Convertible Promissory Note [Member]
Consulting Agreement [Member]
Nirland Limited [Member]
Gain loss on conversion amount.
Alliance Global Partners [Member]
Deferred commission payable annual interest rate.
Alliance Gobal Partners Convertible Note [Member]
Convertible Note Binomial Lattice Model [Member]
Loans Amendment [Member]
October 2024 Nirland Note [Member]
Arrangement fee percentage.
PIPE Warrants [Member]
Disclosure Of Research And Development License Agreement [Text Block]
Astra Zeneca [Member]
Payment to research and devolpment amount.
Sarborg Service Agreement [Member]
Cash payment.
Service Agreement [Member]
SARBORG Additional Agreement [Member]
Second Additional Agreement [Member]
Manoira Joint Development Agreement [Member]
2023 Stock Incentive Plan [Member]
Two Thousand Twenty Three Plan [Member]
Share based compensation arrangement by share based payment award options unvested outstanding number.
Share based compensation arrangement by dhare based payment award options vested and expected to unvested outstanding weighted average exercise price.
Share based compensation arrangement by share based payment unvested award vesting period 1.
Sharebased compensation arrangement by sharebased payment Award options unvested intrinsic value 1.
Sales Agreement [Member]
Corvus Capital Limited [Member]
Board of Directors [Member]
SARBORG Ltd [Member]
SARBORG Services Agreement [Member]
Joint Development Agreement [Member]
Gain on debt extinguishment.
Gain on waiver of accrued interest.
Research and development tax receivable.
Gain on issuance of shares for services.
Loss on conversion of convertible notes payable.
Loss on equity method investment.
Business combination common stock on market value stand
Interest and repayment on strands costs.
Strands costs.
Lease Agreement [Member]
Warrant Liability Disclosure [Text Block]
Purchase Agreement Corvus [Member]
Pre Funded Warrant [Member]
General and administrative expenses.
Other expense.
Gain loss on equity method investment.
Public Warrants [Member]
A.G.P. Warrants [Member]
March 2024 Warrants [Member]
April 2024 Warrants [Member]
AGP 2024 Warrants [Member]
Clinical Asset Development [Member]
Related Parties [Member]
Legal and Professional Fees [Member]
Accounting and Audit Fees [Member]
Salaries Payroll and Stock Based Compensation [Member]
Other [Member]
Exercise of warrants attributable to the sale of previously controlled subsidiary.
Exercise of warrants attributable to the sale of previously controlled subsidiary, shares
Issuance of common stock for services related party.
Deferred cash payable for investment in related party.
Change in fair value of convertible notes payable.
Loss on equity method investment.
ELOC [Member]
ELOC Amendment No. 2 [Member]
Senior Secured Promissory Note with J.J. Astor and Co [Member]
Twenty Four Equal Weekly Installments [Member]
Ascent Note Conversions and Settlement [Member]
Other interest expense.
Expenses other.
Proceeds from market offering program.
Assets, Current
Assets
Liabilities, Current
Liabilities
Equity, Attributable to Parent
Liabilities and Equity
Operating Income (Loss)
Other Nonoperating Expense
Nonoperating Income (Expense)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent
Shares, Outstanding
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent
Shares Granted, Value, Share-Based Payment Arrangement, before Forfeiture
Shares Issued, Shares, Share-Based Payment Arrangement, before Forfeiture
Gain (Loss) on Extinguishment of Debt
Unrealized Gain (Loss), Foreign Currency Transaction, after Tax
LossOnDisposalOfCryptoHoldings
Increase (Decrease) in Prepaid Expense and Other Assets
Increase (Decrease) in Accounts Payable
IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities
Cash Provided by (Used in) Operating Activity, Including Discontinued Operation
PurchaseOfEquipmentAndClinicalAssets
Cash Provided by (Used in) Investing Activity, Including Discontinued Operation
RepaymentOfNotesPayableRelatedParties
Repayments of Notes Payable
RepaymentOfConvertibleNotesPayableRelatedParties
Repayments of Convertible Debt
Cash Provided by (Used in) Financing Activity, Including Discontinued Operation
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Excluding Exchange Rate Effect, Including Discontinued Operation
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Including Discontinued Operation
Forgone Recovery, Individual Name
Outstanding Recovery, Individual Name
Awards Close in Time to MNPI Disclosures, Individual Name
Trading Arrangement, Individual Name
Non-Rule 10b5-1 Arrangement Modified [Default Label]
Convertible Notes Payable [Text Block]
Warrant Liability Disclosure [Text Block]
Equity Method Investments [Policy Text Block]
NetLiabilities
Convertible Debt, Fair Value Disclosures
Debt Instrument, Convertible, Beneficial Conversion Feature
Interest Expense, Operating and Nonoperating
Accounts Payable and Other Accrued Liabilities, Current
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted-Average Remaining Contractual Term
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingNumber
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToUnvestedOutstandingWeightedAverageExercisePrice
ShareBasedCompensationArrangementByShareBasedPaymentUnvestedAwardVestingPeriod1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedIntrinsicValue1
Interest Income, Other
GainOnWaiverOfAccruedInterest
Other Nonoperating Income
Other interest expense
LossOnEquityMethodInvestments
Other Nonoperating Income (Expense)
GeneralAndAdministrativeExpenses